Ono Pharmaceutical Co., Ltd. (OPHLY)
OTC Markets OTCPK · USD · Healthcare · Drug Manufacturers - General
$5.24 (-0.57%) as of
Key statistics
- Market cap
- 7.39B
- P/E (TTM)
- 14.97
- Forward P/E
- 2.31
- EPS (TTM)
- 0.35
- Dividend yield
- 3.21%
- 52-week range
- 3.82 – 5.75
- Beta
- 0.14
- Revenue (TTM)
- 504.41B
- Profit margin
- 15.12%
- Volume
- 4.12k
About Ono Pharmaceutical Co., Ltd.
Ono Pharmaceutical Co., Ltd. produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo intravenous infusion and Kyprolis intravenous injection for malignant tumors; Emend capsule intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; Mektovi, Velexbru, and Braftovi capsules for malignant tumors; and ADLUMIZ tablets for cancer cachexia. The company also provides Glactiv tablets for type 2 diabetes; Forxiga tablets for diabetes, chronic heart failure, and chronic kidney disease; Onoact intravenous infusion for tachyarrhythmia; Opalmon tablets to treat peripheral circulatory disorder; Coralan for chronic heart failure; Orencia injections for rheumatoid arthritis; Rivastach patches for Alzheimer's disease; Ongentys tablets for Parkinson's disease; Parsabiv for the treatment of secondary hyperparathyroidism; Staybla tablets for overactive bladder; Onon capsules and Dry Syrups for bronchial asthma and allergic rhinitis; and Joyclu intra-articular injection for the improvement of joint function, as well as Recalbon tablets for osteoporosis. In addition, it develops products for hepatocellular and urothelial carcinoma; ovarian, bladder, prostate, pancreatic, gastric, esophageal, colorectal, thyroid, cell lung, and breast cancer; acute myeloid leukemia; solid tumors; myelodysplastic syndrome; melanoma; T-cell lymphoma; tachyarrhythmia; pemphigus; scleroderma; seizures; diabetic polyneuropathy; neurodegenerative diseases; autoimmune diseases; narcolepsy; and thrombosis. The company has strategic collaboration with Adimab LLC; Turbine Ltd.; Harvard University; Sibylla Biotech; Congruence Therapeutics; and Aitia, Inc. for drug discovery of novel therapeutic targets for neurological diseases. Ono Pharmaceutical Co., Ltd. was founded in 1717 and is headquartered in Osaka, Japan.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Headquarters
- Osaka, Japan
- Employees
- 4,206
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.